umu.sePublications
Change search
ReferencesLink to record
Permanent link

Direct link
Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
Radiumhemmet, CancerCentreKarolinska, Karolinska Hospital, Stockholm, Sweden. Department of Oncology, University Hospital, Uppsala, Sweden.
Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Herts, United Kingdom.
Radiumhemmet, CancerCentreKarolinska, Karolinska Hospital, Stockholm, Sweden. Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Radiumhemmet, CancerCentreKarolinska, Karolinska Hospital, Stockholm, Sweden. Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Show others and affiliations
2001 (English)In: Clinical Immunology, ISSN 1521-6616, E-ISSN 1521-7035, Vol. 99, no 1, 65-74 p.Article in journal (Refereed) Published
Abstract [en]

We have assessed the immunogenicity profile of GM-CSF in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GM-CSF (Escherichia coli-derived) combination therapy. Metastatic CRC patients received a colon carcinoma-reactive antibody and high doses of GM-CSF (425--500 microg/day for 10 days), while other CRC patients and those with myeloma received low doses of GM-CSF (75--80 microg/day for 4 days) as an adjuvant along with appropriate tumor antigens. We found that 55% of the patients (11/20) given high doses of GM-CSF developed GM-CSF-reactive antibodies in comparison with an incidence of only 16% (4/25) in patients given low doses of GM-CSF. None of the patients developed neutralizing antibodies and so the biological effects of GM-CSF were not compromised. A majority of patients (80%) (36/45) also developed antibodies to E. coli proteins that were present as trace contaminants in the GM-CSF product. Treatment with recombinant GM-CSF products, therefore, may induce antibodies against this cytokine depending on the regimen and the amounts used. In this study, multiple immunizations with low doses of GM-CSF was associated with a low incidence of GM-CSF antibodies, which did not neutralize the effect of the cytokine. This therapeutic strategy was effective in inducing adjuvant-type effects and needs to be explored in further clinical trials with this cytokine.

Place, publisher, year, edition, pages
2001. Vol. 99, no 1, 65-74 p.
Keyword [en]
GM-CSF, antibodies, GM-CSF, immunostimulation, cancer
National Category
Surgery
Identifiers
URN: urn:nbn:se:umu:diva-126908DOI: 10.1006/clim.2000.4999PubMedID: 11286542OAI: oai:DiVA.org:umu-126908DiVA: diva2:1038872
Available from: 2016-10-20 Created: 2016-10-20 Last updated: 2016-10-20

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Strigård, Karin
In the same journal
Clinical Immunology
Surgery

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 10 hits
ReferencesLink to record
Permanent link

Direct link